anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain composite particles which show excellent spreading property, orienting property, shielding property, etc., when the particles are compounded in a cosmetic material or the like, which show properly controlled aggregating property of metal (compd.) fine particles and catalytic reactivity, and which are excellent in such a use as to shield from UV rays, by surrounding metal (compd.) fine particles with silica having a specified or smaller percentage of a crystalline isolated silicate amt. to make a composite material. SOLUTION: The silica used has &lt;10% crystalline isolated silica measured by X-ray diffraction analysis. The metal (compd.) fine particles have 0.01 to 0.5 μm primary particle size. The primary particles of the composite particles preferably substantially have a flake-like form. Each flake-like particle has 0.001 to 1 μm thickness and at least 5 ratio (aspect ratio) of the max. length of the flake to the thickness. The composite particles are obtd. by using a silica sol as the starting material obtd. by dealkalization of an alkali silicate soln., dispersing the metal (compd.) fine particles in the sol, and subjecting the silica sol to hydrothermal treatment.
PURPOSE: To obtain a curing agent for brain edema containing a carbostyril derivative as an active component. CONSTITUTION: This curing agent contains a compound of the formula (R&lt;1&gt; is OANR&lt;2&gt; R&lt;3&gt; ; A is a lower alkylene; R&lt;2&gt; and R&lt;3&gt; are each H or a lower alkanoyl; a bond between carbons at 3 and 4 positions of carbostyril ring is a single bond or a double bond) or its salt in an amount of 1-70wt.%, preferably 5-50wt.% as an active component. As the compound of the formula, 1- 1-[4-(3- acetylaminopropoxy)benzoyl]-4-piperydinyl}-3,4-dihydrocarbostyril can be used. The active component can be formulated into an oral agent, an injection, a suppository, etc., after compounding with an arbitrary component in an adequate amount by a conventional method. The agent is administered at a dose of 0.6-50mg/kg/day in terms of the active component. The compound of the active component is preferably contained in a unit administration formulation in an amount of 10-1000mg.
The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5&#39; NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.
FIELD: medicine.SUBSTANCE: haemorrhoidectomy involving removing haemorrhoids en bloc with an anal wound closure is followed by daily dressings from the first postoperative day with using the antibacterial preparation Levomecol. That is combined with a therapeutic parenteral administration of standard analgesics and taking sitting baths and conducting a local physiotherapy. The preoperative preparation involves prescribing the complex immunomodulator Kipferon presented in the form of suppositories containing 500000 IU of interferon alpha-2 and 60 mg of complex immunoglobulin preparation. The preparation is administered in a dose of one suppository twice a day for 5 days preceding the haemorrhoidectomy. Then, administering the preparation is continued once a day in the same dose from the second to the eleventh postoperative day. The preoperative preparation is also added with prescribing the phlebotonic diosmin (Venarus, Detralex) orally in a dose of 500 mg twice a day for 3 days preceding the haemorrhoidectomy and continued in the same dose twice a day from the first to eighth postoperative day. Besides, from the second postoperative day the osmotic laxative Lactulose is administered orally in a dose of 15-25 ml once until the patient has an unassisted defecation.EFFECT: lower postoperative post-defecation pain syndrome as estimated by VAS analogue scale, less manifested perianal tissue oedema within the operative tissues, shorter wound epithelisation as shown by a cytological pattern of impression smears, achieved adequate elimination of the postoperative complications in the form of bleedings, reflex urinary retention, formation of deforming adhesions, reduced bacterial content of the anal wounds, shorter time of patient&#39;s anal sphincter hypertonus, as well as adequate time of postoperative defecation recovery.3 ex
A multi-phase solid toilet article whose phases are separated by a membrane, and processes for making the article are described. Each phase is reproducibly fabricated to form an article allowing the user to sequentially or simultaneously derive benefits from the different materials contained in the article&#39;s layers. The membrane is either at least partially water soluble or dispersible in the case of a product used with water, or shearable in the case of a cosmetic product which is applied directly to or rubbed on the skin. The membrane material is selected to dissolve or disintegrate with product use, so as to accomplish its intended function of separating the different cosmetic materials until they are consumed. The flowable toilet or cosmetic formulations are simultaneously or separately transferred into the mold, simultaneously or separately allowed to harden, where the membrane divider is not removed and becomes a part of the finished product. The hardened multi-phase article is finally ejected from the mold.
The invention provides a traditional Chinese medicine combination for treating bone injury and fracture. The traditional Chinese medicine combination for oral administration comprises the following crude drugs: Indian bread, red sage root, cornus officinalis, acanthopanax bark, rhizome of Sichuan lovage, large leaf gentian root, loranthus muberry mistletoe, achyranthes root, safflower, ground beetle, caulis spatholobi, rhizome of drynaria, giant knotweed, psoralea fruit, elderberry, buck grass, cassia twig, earthworm, red peony root, heroubill geranium, ledebouriella root and epimedium; the traditional Chinese medicine combination for external use comprises the following raw materials: anisetree bark, myrrh, frankincense, dipsacus root, notoginseng, safflower, dragon&#39;s blood, nux vomica, black catechu, radix aconiti preparata, cassia, caulis impatientis, dahurian angelica root, triperygium wilfordii, Chinese clematis, notopterygium root, earthworm and dried body of scorpion. The traditional Chinese medicine combination has the efficacies of promoting blood circulation to remove blood stasis, promoting reunion of fractured bones, removing stasis to relieve pain and promoting focus repair, and is applicable to the treatment of various types of bone injury and fracture, and is high in cure rate. The traditional Chinese medicine combination ensures that patients are free from the pain of bone fracture and are not required to take strong paregoric. The traditional Chinese medicine combination ensures that callus is rapidly formed and the physiological healing stage is obviously advanced, thereby achieving the purpose of treating bone injury and fracture. The traditional Chinese medicine combination for oral administration has the effects of relieving distension, relieving pain, eliminating stasis, engendering the new and promoting the callus growth, and the traditional Chinese medicine combination for external use can ensure that the callus is rapidly formed and the physiological healing stage is obviously advanced.
PURPOSE: To obtain an agent for lowering nephrotoxicity of medicine such as platinum complex compounds, containing, spherical activated carbon, capable of retaining the antineoplastic action of platinum complex compounds, esp. of cisplatin as active ingredient and capable of markedly lowering the nephrotoxicity after administering such a compound without the need of forced water dose or any diuretic agent administration. CONSTITUTION: This nephrotoxicity lowering agent contains, as active ingredient, spherical activated carbon [for example, petroleum-based pitch-derived spherical activated carbon produced by infusibilizing pitch made finely spherical inn a molten state using oxygen followed by baking at 600-1000 deg.C in an inert atmosphere to effect carbonization followed by activation at 850-1000 deg.C in steam, having a diameter of 0.05-2 (esp. 0.1-1) mm, specific surface area of 500-2000 (esp. 700-1500) m&lt;2&gt; /g, and the content of voids each having 100-75000Å pore radius of 0.01-1 (esp. 0.05-0.8) ml/g]. It is preferable that the formulation of this nephrotoxicity lowering agent be capsules, stick or divided package.
A method for utilizing a magnetically controlled pump implanted into a patient&#39;s brain or other organ for treatment of a solid tumoral mass. The pump delivers a plurality of medicating agents, including viral and non-viral vectors for gene therapy, and cell therapy, at a controlled rate, corresponding to the specific needs of the patient. The pump comprises a flexible double walled pouch that is formed from two layers of polymer. The pouch is alternately expanded and contracting by magnetic solenoid. When contracted, the therapeutic agent is pushed out of the pouch through a plurality of needles. When the pouch is expanded, surrounding fluid is drawn into the space between the double walls of the pouch from which it is drawn through a catheter to an analyzer. In cases where a tumor resection is not performed, or does not permit use of the MBP device, a catheter will be implanted in or adjacent to the tumoral region. Fluid drawn from the patient is analyzed. The operation of the apparatus and hence the treatment is remotely controlled based on these measurements and displayed through an external controller.
A process for the production of a &#34;somatic antigen&#34; vaccine comprises selecting bacteria, culturing the latter on a suitable nutrient medium, which includes an amino acid which is utilised in the formation of cell walls by said bacteria within the &#34;critical concentration range&#34;, harvesting the resulting growth, inactivating and then lysing the bacteria.  The &#34;critical concentration range&#34; of the amino acid is generally between 0.1-5.0% w./v. of the nutrient medium.  It is defined as the range of concentration between the concentration above which the growth rate of a bacterium in a nutrient medium containing the amino acid starts to decrease and the concentration at which growth ceases. Specified amino acids are glycine, L-proline, DL-valine, L-histidine, DL-aspartic acid and L-arginine.  Lysis may be carried out using a proteolytic enzyme. The examples relate to the preparation of meningococcus, staphylococcus, mastitis, streptococcus, and blackleg vaccines.
A method and kit for determining the responsiveness of a human to vitamin treatment of migraine is provided, wherein an A66G methionine synthase reductase (MTRR) genotype indicates the responsiveness of a human to B complex vitamin treatment of migraine. AG heterozygotes and AA homozygotes have a relatively increased responsiveness to vitamin treatment of migraine. A GG genotype is indicative of a relatively reduced or lower responsiveness to vitamin treatment compared to an A allele carrier. The method and kit may detect an isolated nucleic acid or an encoded protein, due to a methionine/isoleucine polymorphism encoded by the A66G polymorphism. A method of treatment of migraine using vitamins is also provided, wherein the responsiveness of the patient to vitamin treatment has been assessed by determining the patient&#39;s A66G genotype. The vitamins are typically vitamin B6, vitamin B12 and folic acid.
PURPOSE:A beautifying cosmetic having a little change in browing phenomena with time after pharmaceutical manufacturing, containing an isoflavon compound such as daidzein, daidzin, genistin, etc. obtained from an extracted material of soybeans, arrowroot, etc. CONSTITUTION:A beautifying cosmetic containing one or more isoflavon compounds selected from daidzein, diadzin, genistein, and genistin, having fundamental skeleton shown by the formula obtained from an extracted material of soybean, arrowroot (Pueraria). The compounds have strong inhibitory action on the formation of melanin, are easily manufactured into pharmaceutical preparation, have a little change in browing phenomena with time, and advantageously made into preparation. The content of isoflavon compound is about 0.005- 0.1wt%. A crude extract containing isoflavon can be used without isolating the compound, and, in this case, the total amount of the isoflavon compound in the preparation is preferably &gt;=0.02wt%.
The present invention relates to treatment of joint or muscle pain and, in particular, combinations of ingredients for such treatment. The invention provides a composition, which includes the following components: emu oil, a salicylate analgesic agent, devil&#39;s claw, and ginger. The components are present in the composition in an amount sufficient to alleviate joint or muscle pain in a mammal in need thereof. A composition having essentially emu oil, a salicylate analgesic agent, devil&#39;s claw and ginger is also provided. The invention further provides a method for alleviating joint or muscle pain in a mammal. The method includes administering topically to the mammal the composition of the present invention.
A system for dispensing pills includes an automatic pill dispenser and a data center. The automatic pill dispenser can store different kinds of pills. The data center is connected to the automatic pill dispenser. The data center includes a cloud server, which stores patient&#39;s information. The patient&#39;s information includes patient&#39;s identification information and pill schedule. The automatic pill dispenser gets the pill schedule based on validated identification information, and can select different kinds of pills according to the pill schedule.
Disclosed herein are compositions, methods, and systems for enhancing survival of mammalian cells frozen at low temperatures. In many embodiments, the cells may include stem cells that may survive at an enhanced rate relative to other cells. In some embodiments, the compositions may include Wharton&#39;s Jelly, and may optionally include DMSO and albumin, for example human serum albumin. However, in various embodiments, the disclosed compositions comprising Wharton&#39;s Jelly may eliminate or reduce the need for traditional cryopreservatives. In some embodiments, the disclosed compositions, methods, and systems may preferentially enhance survival of stem cells, for example mesenchymal stem cells. In some embodiments, the cells may be derived from umbilical cord tissue, for example Wharton&#39;s Jelly.
PURPOSE:To provide a transcutaneous absorption composition containing an ointment base composed mainly of a hydrophobic base and a calcitonin gene relating peptide, having excellent stability and useful as a wound-healing agent. CONSTITUTION:This transcutaneous absorption composition contains an ointment base and a calcitonin gene relating peptide (abbreviated as CGRP) or its salt. The ointment base is a mineral oil and fat base (e.g. liquid paraffin), an animal or vegetable oil and fat base (e.g. lard and camellia oil) or a mixture of two or more kinds of the bases and the amount of the ointment base is 60-100wt.% based on the total composition. The composition is further incorporated with &lt;=40wt.% of a dissolution assistant selected from polyethylene glycol, glycerol, propylene glycol or their mixture. The CGRP is human-a-calcitonin gene relating peptide or desalanyl-deamino-avian-calcitonin gene relating peptide. It can be directly applied to the wounded part to promote the re-epithelialization and the formation of granulation tissue of the wounded part, suppress the inflammatory cell infiltration and promote the arterialization.
Systems and methods provide visual presentation of clinical evidence to a user in association with a patient&#39;s anatomy. In certain examples, a patient information interface system to present an aggregated, graphical view of patient anatomy and history includes a data store to include images and patient history information and a processor to implement a user interface to accept user input. The processor provides a plurality of graphical representations of a human anatomy. Each graphical anatomy representation is to provide a view of a body system. Each graphical anatomy representation is to include one or more indicators corresponding to clinical events that have occurred in connection with a patient in the body system and are viewable through the graphical anatomy representation. Each of the one or more indicators is to be located at an anatomical location on the graphical representation affected by the clinical event corresponding to the indicator.
A personal care composition may have an isosorbide diester having the formula (I): wherein R&#39; and R&#34; are independently selected from a straight or branched C 1-30  chain, which may be saturated or unsaturated. The composition may further comprise a solid UV active soluble in the isosorbide diester and a dermatologically acceptable carrier. The personal care composition may be in the form of an emulsion having an aqueous phase comprising water and an oil phase. The oil phase may comprise the isosorbide diester and a solid UV active soluble in the isosorbide diester. In a particular embodiment, the solid UV soluble in the isosorbide diester UV active may be selected from 4-tert-butyl-4&#39;-methoxy dibenzoylmethane, bis-ethylhexyloxyphenol methoxyphenyl triazine, and combinations thereof. Methods of making the aforementioned personal care compositions are disclosed.
&lt;P&gt;PROBLEM TO BE SOLVED: To shorten processing time for displaying three-dimensional data of a subject comprising a group of a number of two-dimensional images.  &lt;P&gt;SOLUTION: A group file comprising a plurality of two-dimensional data files respectively indicating a plurality of photographed three-dimensional images is received. From a header including image-related information of the two-dimensional data files, relating information to relate the two-dimensional image data files for each three-dimensional image and position information of the two-dimensional image data files are extracted. The extracted image-related information is recorded by the unit of the three-dimensional image. Based on the relating information and the position information, rearranging of the group files and connection of the group files to a single image file are carried out. Either of the single image file and the group file is recorded.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system for enabling a person to receive a safe medication at ease even in his/her home.  &lt;P&gt;SOLUTION: The system for supporting the infusion of a medicine in the home collates an in-home patient and mounts an infusion bag on an infusion pump so as to read information of an IC tag attached to the infusion bag, the IC tag attached to the patient, and the IC tag attached to a medical worker. The information are displayed in the display part of the infusion pump and transmitted to the site of a primary doctor (personal doctor) via an information communication network. The content of the information is recognized, the infusion pump is operated based on a s tart operation, and then, the infusion of the medicine is supported in residence. After the infusion of the medicine is terminated, information about the termination is transmitted from the infusion pump to the primary doctor (family doctor) site, and also, the electronic medical chart of a server stores prescription (administration) data such as health insurance points, a primary medical worker, start time, and end time.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The system includes automatic physiological parameter measuring apparatus (20). The data is automatically transmitted and processed with the measuring apparatus automatically connected (30) to an information server (10) via a switched telephone network (14) and a digital transmission network (12). The server identifies the connected apparatus.  The storage, processing and information terminal connection are installed on the doctor&#39;s premises. The doctor&#39;s terminal can transmit at regular intervals or immediately in an emergency. A central monitor unit checks and coordinates activities and sends out prescriptions. Monitor times are adjusted to the patients needs.
Liquid treating agent admitted at 24 is applied to granular material within drum 10. The drum contains a helical mixing and conveying device (not shown) which is rotatable by a reversible motor 14. In use the drum is swung about axis 12 and the direction of rotation of motor 14 and hence the device is reversed each time drum axis 13 passes through the horizontal, so that the material is always conveyed towards the higher end of the drum. The drum is evacuated through fitting 16, the material enters at 22 and the treated product is removed at 26. Products treated are exemplified as acetyl salicylic acid treated by hydroxypropylmethyl cellulose and talc in methylene chloride, sugar pellets treated with zein and talc in alcohol and tablets treated with hydroxypropylmethyl cellulose and talc in methylene chloride and acetone. &lt;IMAGE&gt;
PURPOSE:To obtain the cured body which has high malleability and ductility, can be easily molded, allows curing reaction in a neutral reaction, has high strength and does not harm biotissue by dissolving a powder material contg. alpha-tricalcium phosphate and/or tetracalcium phosphate and polysaccharides selected from carboxymethyl chitin, glycol chitin, pullulan, and chitosan into an aq. acidic soln. at such ratios at which a specific viscosity is attained. CONSTITUTION:The alpha-tricalcium phosphate is produced by bringing calcium carbonate and calcium pyrophosphate into reaction. The tetracalcium phosphate is produced by bringing calcium carbonate and calcium pyrophosphate. The aq. acidic soln. to be used as a curing liquid contains various kinds of inorg. and org. acids which are dissolved therein. The polysaccharides are preferably carboxymethyl chitin, glycol chitin, pullulan, and above all chitosan. The polysaccharides are dissolved into the acidic aq. soln. at such a ratio at which the generated curing liquid has &gt;=70cp, more preferably 100 to 2000cp viscosity at room temp.